Vertex said total revenue for Q1 2025 (ended March 31) was $2.77 billion, up 3% from Q1 2024. The company cited continued performance of TRIKAFTA/KAFTRIO and an early contribution from the U.S. launch of ALYFTREK as the main drivers.

1. 01

   Vertex said total revenue for Q1 2025 (ended March 31) was $2.77 billion, up 3% from Q1 2024. The company cited continued performance of TRIKAFTA/KAFTRIO and an early contribution from the U.S. launch of ALYFTREK as the main drivers.

2. 02

   Vertex said GAAP net income for Q1 2025 was $646 million, down from $1.1 billion in Q1 2024. The company attributed the decline to higher operating expenses and an intangible asset impairment charge of $379.0 million related to VX-264.

3. 03

   Vertex said it raised the low end of its full-year 2025 total revenue guidance by $100 million to a new range of $11.85 billion to $12 billion. The previous range was $11.75 billion to $12 billion. The company based the guidance on continued growth in CF, continued uptake of CASGEVY and early contributions from JOURNAVX.

4. 04

   Vertex said cash, cash equivalents and total marketable securities as of March 31, 2025 were $11.4 billion, up from $11.2 billion as of December 31, 2024. The company said cash flows from operating activities were the main driver of the increase, partially offset by share repurchases.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.